Publications by authors named "Neal Sule"

Claim this Profile
M
Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials.
María-Victoria Mateos, Suzanne Trudel, Hang Quach, Paweł Robak, Meral Beksac, Neal Sule

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.
Meletios A Dimopoulos, Meral Beksac, Ludek Pour, Sosana Delimpasi, Vladimir Vorobyev, Neal Sule

Lancet Haematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Comprehensive Exposure-Response Analysis of the DREAMM-8 Study.
Patrick Hanafin, Yu Liu Ho, Theodoros Papathanasiou, Giulia Fulci, Neal Sule

Target Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
Meletios Athanasios Dimopoulos, Meral Beksac, Ludek Pour, Sosana Delimpasi, Vladimir Vorobyev, Neal Sule

N Engl J Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
Meletios Athanasios Dimopoulos, Vania T M Hungria, Atanas Radinoff, Sosana Delimpasi, Gabor Mikala, Neal Sule

Lancet Haematol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN).
Shuying Yang, Laurie A Lee, Neal Sule, Andrew Fowler, Guy Peachey

Clin Pharmacokinet· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
Laurie A Lee, Zelie Bailes, Neil Barnes, Louis-Philippe Boulet, Dawn Edwards, Neal Sule

Lancet Respir Med· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis